If you are on the fence about what to do with your GSK shares, you are not alone. The stock has seen some interesting moves ...

GSK stock has seen a modest increase in its Fair Value Estimate, climbing from $16.51 to $16.63 per share while the discount ...

GSK GSK stock has risen 16.9% year to date compared with an increase of 7.0% for the industry. The stock has also outperformed the sector and the S&P 500 index, as seen in the chart below. The stock ...

Unlike peers, GSK plc faces limited Loss of Exclusivity risk, supporting steady revenue projections and justifying higher ...

GSK plc’s strong oncology growth, highlighted by Ojjaara sales and an upgraded 2025 outlook, earns a continued 'Buy' rating.

GSK’s (LSE: GSK) share price is down 19% from its 15 May one-year traded high of £18.19. This could flag that a business is fundamentally worth less than it was before. Or it could highlight a bargain ...

GSK GSK stock has risen 21.5% in the past six months. The consistently strong performance of the Specialty Medicines unit, regulatory and pipeline successes and an optimistic outlook for the long term ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service ...

GSK (NYSE:GSK – Get Free Report) is projected to release its Q1 2025 earnings data before the market opens on Wednesday, April 30th. Analysts expect GSK to post earnings of $1.06 per share and revenue ...